United States: An Early Test For The USPTO’S Eligibility Analysis

Just last week, the USPTO released its revised subject matter eligibility guidance (2014 Interim Guidance on Patent Subject Matter Eligibility "Interim Guidance" reviewed in my prior post of December 16th, 2014). The Interim Guidance replaced the March 2014 Guidance that was much-criticized for its expansive application of U.S. Supreme Court jurisprudence relating to the judicial exceptions to patent-eligibility: abstract ideas, laws of nature and natural phenomenon. Unlike the March 2014 Guidance (that was not circulated to the public for comment prior to its issuance), the Interim Guidance notes that the USPTO's analysis of patent-eligibility will be an iterative process continuing with "periodic supplements based on developments in patent subject matter eligibility jurisprudence and public feedback." Interim Guidance at page 4. Embedded within footnote 5 of the Interim Guidance, the USPTO references an appeal pending before the Federal Circuit – University of Utah Research Foundation v. Ambry Genetics Corp. (In re BRCA1- & BRCA2- Based Hereditary Cancer Test Patent Litigation), No. 14-1361 (Fed. Cir. Filed Mar. 18, 2014 ("Myriad II") that may impact the USPTO's Interim Guidance. Interestingly, the next day on December 17th, 2014 the Federal Circuit issued its Myriad II decision (attached here) holding that Myriad's asserted claims were not patent-eligible. The decision is interesting not only because it evaluates yet more claims from Myriad's impressive patent portfolio but also because it provides an early test of the USPTO's Interim Guidance.

Myriad's Asserted Patent Claims

The history of the dispute and the oral argument are covered in my prior posts of September 29th and October 20th, 2014, respectively. The claims at issue relate to the tools and methods that support Myriad's successful BRCA1/2 genetic tests.

Several plaintiffs that include Myriad Genetics, Inc. (collectively "Myriad") sought to enjoin the alleged infringement by defendant Ambry Genetics Corp. of six claims of three patents: claims 7 and 8 of U.S. Patent No. 5, 753,441 (the '441 patent); claims 16 and 17 of U.S. Patent No 5,747,282 (the '282 patent); and claims 29 and 30 of U.S. Patent No. 5,873,492 (the '492 patent). The District Court for the District of Utah denied Myriad's motion for preliminary injunction. Myriad appealed.

The Composition Claims – Primer Pairs

Four composition of matter claims directed to primer pairs were considered on appeal. Claim 16 of the '282 patent was considered representative:

"A pair of single-stranded DNA primers for determination of a nucleotide sequence of a BRCA1 gene by a polymerase chain reaction, the sequence of said primers being derived from human chromosome 17q, wherein the use of said primers in a polymerase chain reaction results in the synthesis of DNA having all or part of the sequence of the BRCA1 gene."

Claim 17 of the '282 patent and claims 29 and 30 of the '492 patent were considered similar to claim 16 of the '282 patent.

The Federal Circuit began its analysis by referring to the holding of the 2013 Myriad decision (Molecular Pathology v. Myriad, 133 S. Ct. 2107 (2013) ("Myriad I"), wherein the U.S. Supreme Court determined that isolated genomic DNA and DNA fragments were not patent-eligible. cDNA, being a synthetic molecule made by man, was patent-eligible. In evaluating the claims directed to primer pairs, the Federal Circuit determined that primer pairs were more similar to patent-ineligible isolated DNA fragments than patent-eligible cDNA. The court stated that:

"The primers before us are not distinguishable from the isolated DNA found patent-ineligible in [Myriad I] and are not similar to the cDNA found to be patent-eligible. Primers necessarily contain the identical sequence of the BRCA sequence directly opposite to the strand to which they are designed to bind. They are structurally identical to the ends of DNA strands found in nature."

Slip Op. at page 7.

The Federal Circuit disregard Myriad's arguments that the primers were distinguished from the patent-ineligible DNA fragments adjudicated by the Supreme Court. The Federal Circuit found that even though the primers were single stranded, the process of isolating the single-stranded DNA from the human body did not make it patent-eligible. The court also determined that the function of the primers – to initiate an amplification reaction – was not markedly different from DNA fragments as they appear in nature. The court stated that:

"In fact, the naturally occurring genetic sequences at issue here do not perform a significantly new function. Rather, the naturally occurring material is used to form the first step in a chain reaction—a function that is performed because the primer maintains the exact same nucleotide sequence as the relevant portion of the naturally occurring sequence. One of the primary functions of DNA's structure in nature is that complementary nucleotide sequences bind to each other. It is this same function that is exploited here—the primer binds to its complementary nucleotide sequence. Thus, just as in nature, primers utilize the innate ability of DNA to bind to itself."

Slip Op. at page 9.

The Method Claims – Detecting Sequences

Claims 7 and 8 of the '441 patent related to methods for detecting certain DNA sequences. Claim 7 (revised to include the language of claim 1 from which it depends) was considered representative:

"A method for screening germline of a human subject for an alteration of a BRCA1 gene which comprises comparing germline sequence of a BRCA1 gene or BRCA1 RNA from a tissue sample from said subject or a sequence of BRCA1 cDNA made from mRNA from said sample with germline sequences of wild-type BRCA1 gene, wild-type BRCA1 RNA or wild-type BRCA1 cDNA, wherein a difference in the sequence of the BRCA1 gene, BRCA1 RNA or BRCA1 cDNA of the subject from wild-type indicates an alteration in the BRCA1 gene in said subject[,]

wherein a germline nucleic acid sequence is compared by hybridizing a BRCA1 gene probe which specifically hybridizes to a BRCA1 allele to genomic DNA isolated from said sample and detecting the presence of a hybridization product wherein a presence of said product indicates the presence of said allele in the subject."

Claim 8 (revised to include the language of claim 1, from which it depends) recites:

"A method for screening germline of a human subject for an alteration of a BRCA1 gene which comprises comparing germline sequence of a BRCA1 gene or BRCA1 RNA from a tissue sample from said subject or a sequence of BRCA1 cDNA made from mRNA from said sample with germline sequences of wild-type BRCA1 gene, wild-type BRCA1 RNA or wild-type BRCA1 cDNA, wherein a difference in the sequence of the BRCA1 gene, BRCA1 RNA or BRCA1 cDNA of the subject from wild-type indicates an alteration in the BRCA1 gene in said subject[,]

wherein a germline nucleic acid sequence is compared by amplifying all or part of a BRCA1 gene from said sample using a set of primers to produce amplified nucleic acids and sequencing the amplified nucleic acids."

In analyzing the method claims, the court looked to the Supreme Court's analysis in Association for Molecular Pathology v. United States Patent and Trademark Office, 132 S. Ct. 1794 (2012) and Alice Corp. v. CLS Bank Int'l, 134 S. Ct. 2347, 2354 (2014)("Alice"). The court stated that:

"Recently in Alice the Supreme Court reiterated its two-step test to determine patent eligibility for any claims that allegedly encompass abstract ideas. First, "we determine whether the claims at issue are directed to [a] patent-ineligible concept[]. If so, we then ask, 'what else is there in the claims before us?" ... Here, we treat separately the first paragraphs of claims 7 and 8, which describe the comparison of wild-type genetic sequences with the subject's genetic sequence and correspond to the first step of Alice, and the second paragraphs, which describe the techniques to be used in making the comparisons and correspond to the second step of Alice."

Slip Op. at page 14.

The Federal Circuit stated that the first step of the methods are not patent-eligible because the steps comprise nothing more than comparing sequences. The court also focused on the breadth of the claims, noting that the covered comparisons were not restricted by the purpose of the comparison or the alteration being detected, and therefore may pre-empt future use outside the field of cancer detection.

Having determined that the first step of the claims were abstract ideas under an Alice analysis, the court then looked at the second step to determine if this step alone or in combination with the first step, transform the patent-ineligible method to a patent-eligible one. The court noted that "[t]here must be a further inventive concept to take the claim into the realm of patent-eligibility." Slip Op. at page 16.

The Federal Circuit also determined that the use of conventional methods in the second steps, such as sequencing or hybridization, did not add a further inventive concept to the abstract idea embodied by the first steps of the claims.

Patent-Eligible Applications

The court also dismissed Myriad's argument that the method claims were similar to claim 21 of the '441 patent which Judge Bryson suggested was patent-eligible in the Federal Circuit's earlier 2012 Myriad I decision. Myriad asserted that Judge Bryson indicated that as a first party with knowledge of sequences, they were in an excellent situation to claim applications of that knowledge. The court noted that even if claim 21 was patent-eligible, which the court expressly declined to opine on, the claim was qualitatively different from the method claims at issue in this dispute. The court noted that claim 21 is limited to particular mutations that the inventors had discovered whereas the claims in Myriad II were significantly broader and more abstract, as they claim all comparisons between the patient's BRCA genes and wild-type BRCA genes.

A Review of the USPTO Interim Guidance

The USPTO's Interim Guidance and the Federal Circuit's recent Myriad II decision appear fairly aligned in their respective application of the Supreme Court patent-eligibility precedent. For claims that relate to a product of nature, the court's and the USPTO's analyses consider not only the structural differences between the claimed subject matter and its natural counterpart, but also whether the claimed product exhibits markedly different characteristics from its naturally occurring counterpart in its natural state. Interim Guidance at page 15. However, the USPTO Interim Guidance also notes that if the claimed product does not appear to monopolize or tie-up a judicial exception, it is not necessary to conduct a markedly different analysis. Interim Guidance at page 16. The Federal Circuit's opinion, in contrast, only evaluated the product claims in terms of structural and functional differences between the claimed material and its natural counterpart.

For claims that may related to natural phenomenon or an abstract idea, the current opinion and the Interim Guidance similarly note that the claim elements must be evaluated to determine whether the elements of the claim, considered in both individually and as an ordered combination, are sufficient to ensure that the claim as a whole amounts to significantly more than the exception itself. Interim Guidance at page 20. The Interim Guidance and the Federal Circuit each look to whether a claim contains elements in addition to the judicial exception that amount to significantly more that the judicial exception itself, and that the claim does not monopolize the exception. Interim Guidance on page 21.

Looking Ahead

The USPTO Interim Guidance is less restrictive in its approach to patent-eligibility. Application of the Interim Guidance is anticipated to allow patenting of more nature-based inventions as compared to the 2014 Guidance. However, even with the Interim Guidance, it is clear that the Federal Circuit will not find broad, expansive claims that relate in whole or in part to a judicial exception to subject matter eligibility to be valid and patent-eligible. Thus, challenges remain and patentees should continue to pay careful consideration to the USPTO's Interim Guidance and the evolving jurisprudence involving subject matter eligibility.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

    Disclaimer

    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

    Registration

    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

    Cookies

    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

    Links

    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

    Mail-A-Friend

    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

    Emails

    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

    Security

    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions